The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 08, 2022

Filed:

Apr. 26, 2018
Applicant:

Integrated Dna Technologies, Inc., Coralville, IA (US);

Inventors:

Christopher Anthony Vakulskas, North Liberty, IA (US);

Nicole Mary Bode, Oxford, IA (US);

Michael Allen Collingwood, North Liberty, IA (US);

Garrett Richard Rettig, Coralville, IA (US);

Mark Aaron Behlke, Coralville, IA (US);

Assignee:

Integrated DNA Technologies, Inc., Coralville, IA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C12N 9/22 (2006.01); C12N 15/90 (2006.01); C12N 15/113 (2010.01); C12N 15/87 (2006.01); C12N 15/10 (2006.01); C12Q 1/6897 (2018.01); C12N 15/88 (2006.01); C12P 19/34 (2006.01);
U.S. Cl.
CPC ...
C12N 15/87 (2013.01); C12N 9/22 (2013.01); C12N 15/102 (2013.01); C12N 15/88 (2013.01); C12N 15/90 (2013.01); C12Q 1/6897 (2013.01); C12N 2310/20 (2017.05); C12N 2810/50 (2013.01); C12P 19/34 (2013.01);
Abstract

This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRISPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.


Find Patent Forward Citations

Loading…